Representative before the EPO

Company dna hlbbshaw ltd
no operation time available
938.28
3 offices
active in Legal Services

Representative before the EPO

Employment test 51 - 200 employees
Company dna mathys and squire llp
no operation time available
Headquarter in London and 5 offices
active in Legal Services and Matchmaking and Trading

Representative before the EPO

Employment test 1 - 10 employees
Company dna avidity ip ltd
no operation time available
1107.21
Headquarter in Cambridge and 3 offices
active in Legal Services

We have observed 30 EP applications James Roger Wilding has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after September 23, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11840988

IMMUNOGENIC COMPOSITIONS

IPC classification:
A61K 9/107, A61P 37/04, A61P 31/04, A61K 39/118
Applicant:
Sanofi Pasteur SA
Agent:
Multiple attorneys, Avidity IP Ltd
Status:
GRANT OF PATENT INTENDED
EP11799550

COMPOSITION FOR IMMUNIZATION AGAINST STREPTOCOCCUS PNEUMONIAE

IPC classification:
A61K 39/09
Applicant:
Sanofi Pasteur Limited
Agent:
Multiple attorneys, Avidity IP Ltd
Status:
The patent has been granted
EP12195331

Nicking and extension amplification reaction for the exponential amplification of nucleic acids

IPC classification:
C12Q 1/68
Agent:
Multiple attorneys, Mathys & Squire LLP
Agent:
James Roger Wilding, Avidity IP Ltd
Agent:
Patent Boutique LLP
Status:
EXAMINATION REQUESTED
EP12195333

Nicking and extension amplification reaction for the exponential amplification of nucleic acids

IPC classification:
C12Q 1/68
Agent:
Multiple attorneys, Mathys & Squire LLP
Agent:
James Roger Wilding, Avidity IP Ltd
Agent:
Patent Boutique LLP
Status:
EXAMINATION IN PROGRESS
EP12767452

MONITORING RECOMBINASE POLYMERASE AMPLIFICATION MIXTURES

IPC classification:
C12Q 1/68, C12P 19/34
Applicant:
Alere San Diego Inc
Agent:
Jon Philip Broughton, Patent Boutique LLP
Agent:
Jon Philip Broughton, Broughton IP
Agent:
Multiple attorneys, Avidity IP Ltd
Status:
EXAMINATION IN PROGRESS
EP14717952

TOXOID, COMPOSITIONS AND RELATED METHODS

IPC classification:
A61K 39/02, C07K 14/33
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION IN PROGRESS
EP14722469

TREATMENT OF CANCER USING HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR

IPC classification:
A61P 35/00, C12N 5/0783, C07K 16/30, C07K 14/705, C07K 14/725, A61K 35/14, C07K 16/28
Applicant:
University of Pennsylvania
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION IN PROGRESS
EP14737429

COMPOSITIONS AND METHODS OF IMMUNIZING AGAINST C. DIFFICILE

IPC classification:
A61K 39/00, A61K 39/08
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
GRANT OF PATENT INTENDED
EP13168383

Methods of treating multiple myeloma using combination therapies based on HuLuc63 with bortezomib

IPC classification:
A61K 45/06, A61P 35/00, A61K 39/395, A61K 31/69, A61K 31/454, A61K 31/573
Applicant:
AbbVie Biotherapeutics Inc.
Applicant:
Dana-Farber Cancer Institute, Inc.
Agent:
James Roger Wilding, Avidity IP Ltd
Agent:
Sarah Elizabeth Roques, J A Kemp
Status:
PATENT GRANTED
EP13168364

Methods of Treating Multiple Myeloma Using Combination Therapies based on Anti-CS1 Antibodies

IPC classification:
A61K 45/06, A61K 38/55, A61P 35/00, A61K 39/395, A61K 31/69, A61K 31/454
Applicant:
AbbVie Biotherapeutics Inc.
Applicant:
Dana-Farber Cancer Institute, Inc.
Agent:
James Roger Wilding, Avidity IP Ltd
Agent:
Sarah Elizabeth Roques, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14871351

HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

IPC classification:
A61P 35/00, A61K 48/00, C07K 14/725, C07K 16/46, C12N 15/63, C12N 15/13, C12N 15/62
Applicant:
The Trustees of The University of Pennsylvania - Center for Technology Transfer
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP14872734

REGULATABLE CHIMERIC ANTIGEN RECEPTOR

IPC classification:
C12N 5/0783, C07K 19/00
Applicant:
The Trustees of The University of Pennsylvania - Center for Technology Transfer
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP15704414

ENHANCED ANTIGEN PRESENTING ABILITY OF CAR T CELLS BY CO-INTRODUCTION OF COSTIMULATORY MOLECULES

IPC classification:
C07K 14/705, C12N 5/0783, C07K 14/725
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP15764851

REGULATABLE CHIMERIC ANTIGEN RECEPTOR

IPC classification:
A61K 38/00, A61K 39/00
Applicant:
University of Pennsylvania
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP15719043

TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR

IPC classification:
A61P 35/02, A61K 31/00, A61K 35/17, C12N 5/0783
Applicant:
University of Pennsylvania
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP15745069

TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR

IPC classification:
A61P 35/02, A61K 35/17, A61K 31/436, A61K 39/395, C07K 14/705, C07K 14/725, C07K 16/30, C07K 16/28
Applicant:
The Trustees of The University of Pennsylvania - Center for Technology Transfer
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP15744448

TREATMENT OF CANCER USING A CLL-1 CHIMERIC ANTIGEN RECEPTOR

IPC classification:
C07K 16/28, C07K 14/725, A61K 35/17
Applicant:
University of Pennsylvania
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP15753252

SUBSET-OPTIMIZED CHIMERIC ANTIGEN RECEPTOR-CONTAINING T-CELLS

IPC classification:
C07K 14/705, A61K 35/17
Applicant:
University of Pennsylvania
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
Examination is in progress
EP15756525

ANTI-CD123 CHIMERIC ANTIGEN RECEPTOR (CAR) FOR USE IN CANCER TREATMENT

IPC classification:
A61K 39/395, C07K 16/28
Applicant:
University of Pennsylvania
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP15745335

SORTASE MOLECULES AND USES THEREOF

IPC classification:
C12N 9/64
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
Request for examination was made
EP15753232

COMBINATIONS OF LOW, IMMUNE ENHANCING. DOSES OF MTOR INHIBITORS AND CARS

IPC classification:
A61K 31/4745, A61K 39/00
Applicant:
University of Pennsylvania
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
Request for examination was made
EP15774791

TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY

IPC classification:
C07K 14/735, C07K 14/705, C07K 16/30, C07K 16/28
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
Request for examination was made
EP15791387

BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO CHIMERIC ANTIGEN RECEPTOR THERAPY AND USES THEREOF

IPC classification:
C12N 5/0783, G01N 33/574
Applicant:
University of Pennsylvania
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
Request for examination was made
EP16718786

COMBINATION OF CHIMERIC ANTIGEN RECEPTOR THERAPY AND AMINO PYRIMIDINE DERIVATIVES

IPC classification:
A61K 45/06, A61K 31/506, A61K 31/505, C12N 5/0783
Applicant:
University of Pennsylvania
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
Request for examination was made
EP16720247

METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS

IPC classification:
A61K 35/17, C12N 5/00, C07K 14/705, C07K 14/47, C12N 5/0783
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
Request for examination was made
EP16719733

TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR AND PROTEIN KINASE A BLOCKER

IPC classification:
A61K 39/00, C07K 14/725
Applicant:
University of Pennsylvania
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
Request for examination was made
EP16727261

METHODS FOR IMMUNIZING AGAINST CLOSTRIDIUM DIFFICILE

IPC classification:
A61K 39/08
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
Request for examination was made
EP16750306

METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF IMMUNE CELLS

IPC classification:
A61K 48/00, C07K 16/30, C07K 14/725
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
Request for examination was made
EP16754055

TREATMENT OF CANCER USING CHIMERIC CD3 RECEPTOR PROTEINS

IPC classification:
C07K 14/705, C07K 14/725, C07K 16/30, C07K 16/28
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
Request for examination was made
EP16779217

CAR T CELL THERAPIES WITH ENHANCED EFFICACY

IPC classification:
C07K 14/705, C12N 9/02
Applicant:
University of Pennsylvania
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
Request for examination was made

Please Sign in to use this feature